Exelixis fails to meet primary objective in XL880 trial

By Elaine Rigoli

Tampa, Fla., June 5 - Exelixis, Inc. said updated results from a phase 1 trial of XL880 in patients with advanced solid malignancies showed that, although the compound is well tolerated, a maximum tolerated dose has not yet been established.

The primary objective of the phase 1 dose escalation trial was to establish a maximum tolerated dose and to assess safety and tolerability of the oral administration of XL880.

The company said it has treated 25 patients across five dose levels ranging from 0.1 to 1.6 mg/kg.

Nineteen patients had been followed for at least three months.

Two dose-limiting toxicities were encountered. One episode of grade 3 lipase elevation and one episode of grade 3 transaminase elevation were reported, the company said in a news release.

Exelixis is a biotechnology company located in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.